Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14155MR)

This product GTTS-WQ14155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14155MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5794MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ8167MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ10241MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ4916MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ7830MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ5073MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ7736MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ7108MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW